Leerink Swann Upgrades Illumina; Revises Estimates for Life Tech, Thermo Fisher, Others | GenomeWeb

NEW YORK (GenomeWeb News) – Leerink Swann today upgraded Illumina to an Outperform rating, saying the demand for its HiSeq next-generation sequencing platform has normalized, while interest among researchers in sequencing has remained high.

Separately, the investment firm revised estimates for Life Technologies, Thermo Fisher Scientific, Affymetrix, PerkinElmer, Bio-Rad Laboratories, Bruker, and Waters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.